Potential of high-dose cefepime/tazobactam against multiresistant Gram-negative pathogens

Journal of Antimicrobial Chemotherapy

Volumn 73, Issue 1, 2018, Pages 126-133

  Livermore, David M ^a,b   Mushtaq, Shazad ^b   Warner, Marina ^b   Turner, Simon J ^c   Woodford, Neil ^b  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c GCP Scientific Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; BETA LACTAMASE AMPC; CARBAPENEMASE; CEFEPIME; CEFTAZIDIME; EXTENDED SPECTRUM BETA LACTAMASE; MEROPENEM; PENICILLINASE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TAZOBACTAM; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE INHIBITOR; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID;

ACINETOBACTER; AGAR DILUTION; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; DOSE RESPONSE; DRUG MEGADOSE; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NON-FERMENTER; NONHUMAN; PSEUDOMONAS AERUGINOSA; STENOTROPHOMONAS MALTOPHILIA; ANALOGS AND DERIVATIVES; DRUG COMBINATION; DRUG EFFECT; ENTEROBACTERIACEAE INFECTION; GENETICS; HUMAN; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; CEPHALOSPORINS; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID;

EID: 85040594200     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkx360     Document Type: Article

References (28)

1. Paterson DL, Bonomo RA. Extended-spectrum b-lactamases: a clinical update. Clin Microbiol Rev 2005; 18: 657-86
2. Livermore DM. Determinants of the activity of b-lactamase inhibitor combinations. J Antimicrob Chemother 1993; 31 Suppl A: 9-21
3. Payne DJ, Miller LF, Findlay D et al. Time for a change: addressing R&D and commercialization challenges for antibacterials. Philos Trans R Soc Lond B Biol Sci 2015; 370: 20140086
4. Livermore DM, Hope R, Mushtaq S. Orthodox and unorthodox clavulanate combinations against extended-spectrum b-lactamase producers. Clin Microbiol Infect 2008; 14 Suppl 1: 189-93
5. Paterson DL, KoWC, Von Gottberg A et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum b-lactamases: implications for the clinical microbiology laboratory. JClinMicrobiol 2001; 39: 2206-12
6. European Committee on Antimicrobial Susceptibility Testing. Clinical Breakpoints. http://www.eucast.org/clinical_breakpoints/
7. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-sixth Informational Supplement M100-S26. CLSI, Wayne, PA, USA, 2016
8. TärnbergM,Ostholm-Balkhed A, Monstein HJ et al. In vitro activity of b-lactam antibiotics against CTX-M-producing Escherichia coli. Eur J Clin Microbiol Infect Dis 2011; 30: 981-7
9. Livermore DM, Canton R, Gniadkowski M et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 2007; 59: 165-74
10. Bhatia A, Chungh R, Gupta M et al. Safety, tolerability and pharmacokinetics of WCK 4282 (FEP-TAZ) in healthy adult subjects. In Abstracts of the 26th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, the Netherlands, 2016. Poster P1303. European Society for ClinicalMicrobiology and Infectious Diseases, Basel, Switzerland
11. Medline India. Cefepime tazobactam. http://www.medlineindia.com/anti biotic/cefepime_with_tazobactam.html
12. Ghafur A, Tayade A, Kannaian P. Clinical profile of patients treated with cefepime/tazobactam: a new b-lactam/b-lactamase inhibitor combination. JMicrobiol InfectDis 2012; 2: 79-86
13. Kaur K, Gupta A, Sharma A et al. Evaluation of efficacy and tolerability of cefotaxime and sulbactam versus cefepime and tazobactam in patients of urinary tract infection-a prospective comparative study. J Clin Diagn Res 2014; 8: HC05-8
14. Papp-Wallace KM, Bonomo RA. New b-lactamase inhibitors in the clinic. Infect Dis Clin NorthAm2016; 30: 441-64
15. Livermore DM, Mushtaq S, Warner M et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother 2011; 66: 48-53
16. Livermore DM, Mushtaq S, Meunier D et al. Activity of ceftolozane/tazobactam against surveillance and 'problem' Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles. J Antimicrob Chemother 2107; 72: 2278-89
17. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically-Ninth Edition: Approved Standard M7-A9. CLSI, Wayne, PA, USA, 2011
18. Poirel L, Héritier C, Tolün V et al. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother 2004; 48: 15-22
19. Livermore DM, Mushtaq S, Ge Y. Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus b-lactamaseproducing Enterobacteriaceae. J Antimicrob Chemother 2010; 65: 1972-4
20. VanScoy B, Mendes RE, McCauley J et al. Pharmacological basis of b-lactamase inhibitor therapeutics: tazobactam in combination with ceftolozane. Antimicrob Agents Chemother 2013; 57: 5924-30
21. VanScoy BD, Tenero D, Turner S et al. Pharmacokinetics-pharmacodynamics of tazobactamin combination with cefepime in an in vitro infection model. Antimicrob Agents Chemother 2017; in press
22. Hancock RE, Bellido F. Factors involved in the enhanced efficacy against Gram-negative bacteria of fourth generation cephalosporins. J Antimicrob Chemother 1992; 29 Suppl A: 1-6
23. Davies TA, Page MG, ShangWet al. Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. Antimicrob Agents Chemother 2007; 51: 2621-4
24. Babini GS, Yuan M, Hall LM et al. Variable susceptibility to piperacillin/tazobactam amongst Klebsiella spp. with extended-spectrum b-lactamases. JAntimicrobChemother 2003; 51: 605-12
25. Ohsuka S, Arakawa Y, Horii T et al. Effect of pH on activities of novel b-lactamases and b-lactamase inhibitors against these b-lactamases. Antimicrob Agents Chemother 1995; 39: 1856-8
26. Aktaş Z, Kayacan C, Oncul O. In vitro activity of avibactam (NXL104) in combination with b-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae. Int J Antimicrob Agents 2012; 39: 86-9
27. Papp-Wallace KM, Bethel CR, Distler AM et al. Inhibitor resistance in the KPC-2 b-lactamase, a preeminent property of this class A b-lactamase. Antimicrob Agents Chemother 2010; 54: 890-7
28. Sader HS, Castanheira M, Mendes RE et al. Antimicrobial activity of highproportion cefepime/tazobactam (WCK 4282) against a large number of Gram-negative isolates collected worldwide in 2014. Antimicrob Agents Chemother 2017; 61: pii: e02409-16